

EverLift® Submucosal Lifting Agent results in no foreign body artifacts post endoscopic mucosal resection and endoscopic submucosal dissection

Making informed decisions when selecting a submucosal lifting agent to support the needs of physicians, patients, and administrators

Review conducted by Gary “Taavi” Reiss, MD and Robert M. Najarian, MD

GI Supply, Inc. is a wholly owned subsidiary of Laborie Medical Technologies Corp. For ease of reference, GI Supply, Inc. is referred to as 'Laborie' in this whitepaper

KEY POINTS

1. Laborie's 2021 post-market clinical follow-up study of its 5 mL and 10 mL syringes validated that EverLift Submucosal Lifting Agent does not produce artifacts.
2. The study confirmed that 5 mL pre-filled syringes offer waste-reduction and cost-savings opportunities.
3. Pathologists should at a minimum be made aware of the use of a submucosal lifting agent during polypectomies, endoscopic mucosal resections (EMR), and endoscopic submucosal dissections (ESD).

SUPPORTING PUBLICATIONS

1. “The assessment of submucosal distortion and mass effect seen at follow-up after colorectal endoscopic mucosal resection with ORISE™¹ published in the Journal for Gastrointestinal Endoscopy | 2022
2. “Histologic changes caused by injection of a novel submucosal lifting agent for endoscopic resection in GI agent,”² published in Gastrointestinal Endoscopy | 2021
3. “Features of endoscopic procedure site reaction associated with a recently approved submucosal lifting agent,”³ published in Modern Pathology | 2020

Background: Several published, peer-reviewed papers have addressed the complexities and costs associated with the use of some submucosal lifting agents. The issue is the potential for pathologists to misinterpret the residue as being clinically significant.

Objective: Evaluate the pathology results of EverLift Submucosal Lifting Agent to show any adverse effects as compared to other submucosal lifting agents when used during polypectomies, endoscopic mucosal resections (EMR) and endoscopic submucosal dissections (ESD). Show that EverLift's 5 mL pre-filled syringes offer waste-reduction and cost-savings opportunities.

Results: Data was analyzed from 71 patients (age 37 - 88, median age 63.5), including names and locations of clinical sites, procedure dates, lesion size and description, syringe size, and total volume injected.

Conclusion: Laborie's 2021 post-market clinical follow-up study of its 5 mL and 10 mL syringes validated that, unlike other submucosal lifting agents on the market,

EverLift Submucosal Lifting Agent does not produce artifacts. The study also confirmed that 5 mL pre-filled syringes offer waste-reduction and cost-savings opportunities. There were no reports of intraprocedural patient reactions caused or contributed by the device, no reports of intraprocedural complications at or adjacent to the injection site, and no report of post-procedure (24-hour)-related complications.⁴

EXPERT COMMENTARY

“After completely reviewing the 71 patient cases, I see nothing either in the diagnostic lines, or in the histologic descriptions, that would suggest any artifacts with EverLift. Of note, there appeared to be several cancers included among the samples in a variety of gastrointestinal tract organs, which were confidently diagnosed and described by the pathologists of record without mention of artifact.”

- Robert M. Najarian, MD,
Gastrointestinal Pathologist and Medical Director at University Gastroenterology's Pathology Center.

References

1. Lahr RE, DeWitt JM, Zhang D, Rex DK, Assessment of Submucosal Distortion and Mass Effect Seen at Follow-up After Colorectal Endoscopic Mucosal Resection with ORISE. Gastrointest Endoscopy. 2022 May 9;S0016-5107(22)01663-7.
2. Olivas AD, MD, Setia N, Weber CR, et al. Histologic changes caused by injection of a novel submucosal lifting agent for endoscopic resection in GI lesions. Gastrointestinal Endoscopy. 2021; 2021;93:470-6.
3. Castrodad-Rodríguez CA, Panarelli NC, Adam J. Gersten AJ. Features of endoscopic procedure site reaction associated with a recently approved submucosal lifting agent. Modern Pathology. 2020; 33:1581–1588.
4. Data on file.

USA

T +1 800 522 6743

E gis-orders@laborie.com
W laborie.com

EverLift is a Registered Trademark of GI Supply, Inc.
© 2022 Laborie Medical Technologies Corp. All Rights Reserved.
ORISE is a Trademark of ©2022 Boston Scientific Corporation or its Affiliates. All Rights Reserved.



Learn more